

Allogeneic Tumor Cell Vaccination (Hadasit)**code:** 8-2010-16

Michal Lotem, Hadassah Ein Kerem, Oncology

Need:

Novel approaches for cancer management for advanced stage melanoma patients are a significant unmet clinical need.

Innovation:

A Novel tool for active immunization of cancer patients by using modified tumor cell lines expressing MHC-I and co-stimulatory molecules.

Findings:

The cell line platform is based on successful clinical trials led by Prof. Lotem with both autologous and allogeneic melanoma vaccines.

- "Autologous" melanoma vaccine - Self melanoma tumor cells that induces antitumor immune responses that affect patient survival and depend on MHC-II expression on vaccine cells.
- Allogeneic melanoma cells expressing HLA-matched molecules.
- Improved immunogenicity of melanoma cells in vitro by de novo expression of a key co-stimulatory molecule.

Indications / Applications:

- Tumor-cell based vaccine with enforced immunogenicity as an "off the shelf product".
- The vaccine is tailor-made for MHC-I matching and enhanced by the expression of co-stimulatory molecule
- The vaccines can be used independently as a single treatment like an adjuvant treatment for metastatic patients or in combinations with other therapies.

Competitive Advantage:

A Novel approach that was tested in clinical trial for high risk or low residual disease melanoma patients – phase I/II Study. The study was designed for patients who had malignant melanoma and following tumor removal are free of disease, or have only very minor residual disease and are at a very high risk of disease recurrence.

Contact for more information:Tal Almog , 054-3187538

Hadasit Medical Research Services & Development Ltd
Mother & Child Pavilion, Hadassah Ein Kerem, Jerusalem , 91120 Israel
Phone: +972-2-6778757, Fax: +972-2-6437712, E-mail: skimhi@hadassah.org.il